Literature DB >> 6264019

Hepatitis B virus, hepatitis A virus and persistently elevated aminotransferases in hemophiliacs.

R J Gerety, M E Eyster, E Tabor, J A Drucker, C J Lusch, D Prager, S A Rice, H S Bowman.   

Abstract

To determine the exposure to hepatitis A and hepatitis B viruses (HAV, HBV) following intravenous replacement therapy in patients with classic hemophilia and to assess the role of these viruses in persistently elevated aminotransferases, sera were studied from 136 patients from 9 months to 67 years of age were transfused with either single-donor cryoprecipitate (CRYO) or Antihemophilic Factor Concentrate (AHF) for periods ranging from a few months to 15 years. Serologic evidence of past or present infection with HBV was detected in 90% of all 136 patients and in 85% of those 34 patients 10 years of age or younger. Sixty-four percent of those with serologic markers of hepatitis B had high titers of antibody to the hepatitis B surface antigen and low titers of antibody to the hepatitis B core antigen. These findings are consistent with the known high frequency of early exposure to HBV in hemophiliacs receiving replacement therapy and with recovery from these hepatitis B infections. Sixteen percent of these patients had persistently elevated aminotransferase levels; HBV could not be implicated as the cause of the enzyme elevations in most of these cases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6264019     DOI: 10.1002/jmv.1890060203

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

Review 1.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Hepatitis B virus infection in multitransfused haemophiliacs.

Authors:  G Nebbia; G A Moroni; L Simoni; M Belli; V Carnelli
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

3.  Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up.

Authors:  M Blombäck; H Kjellman; S Schulman; N Egberg; B Böttiger; B Wiechel
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.